Tuesday, November 18, 2025

 

Ultrasonic device dramatically speeds harvesting of water from the air



The system can be paired with any atmospheric water harvesting material to shake out drinking water in minutes instead of hours.



Massachusetts Institute of Technology

Water Shaker 

image: 

MIT engineers design an ultrasonic system to “shake” water out of an atmospheric water harvester. The design (two prototypes shown in photo) can recover captured water in minutes rather than hours.

view more 

Credit: Ikra Iftekhar





 Feeling thirsty? Why not tap into the air? Even in desert conditions, there exists some level of humidity that, with the right material, can be soaked up and squeezed out to produce clean drinking water. In recent years, scientists have developed a host of promising sponge-like materials for this “atmospheric water harvesting.” 

But recovering the water from these materials usually requires heat — and time. Existing designs rely on heat from the sun to evaporate water from the materials and condense it into droplets. But this step can take hours or even days.  

Now, MIT engineers have come up with a way to quickly recover water from an atmospheric water harvesting material. Rather than wait for the sun to evaporate water out, the team uses ultrasonic waves to shake the water out. 

The researchers have developed an ultrasonic device that vibrates at high frequency. When a water-harvesting material, known as a “sorbent,” is placed on the device, the device emits ultrasound waves that are tuned to shake water molecules out of the sorbent. The team found that the device recovers water in minutes, versus the tens of minutes or hours required by thermal designs. 

Unlike heat-based designs, the device does require a power source. The team envisions that the device could be powered by a small solar cell, which could also act as a sensor to detect when the sorbent is full. It could also be programmed to automatically turn on whenever a material has harvested enough moisture to be extracted. In this way, a system could soak up and shake out water from the air over many cycles in a single day. 

“People have been looking for ways to harvest water from the atmosphere, which could be a big source of water particularly for desert regions and places where there is not even saltwater to desalinate,” says Svetlana Boriskina, principal research scientist in MIT’s Department of Mechanical Engineering. “Now we have a way to recover water quickly and efficiently.”

Boriskina and her colleagues report on their new device in a study appearing in the journal Nature Communications. The study’s first author is Ikra Iftekhar Shuvo, an MIT graduate student in media arts and sciences, along with Carlos Díaz-Marín, Marvin Christen, Michael Lherbette, and Christopher Liem. 

Precious hours

Boriskina’s group at MIT develops materials that interact with the environment in novel ways. Recently, her group explored atmospheric water harvesting (AWH), and ways that materials can be designed to efficiently absorb water from the air. The hope is that, if they can work reliably, AWH systems would be of most benefit to communities where traditional sources of drinking water — and even saltwater — are scarce. 

Like other groups, Boriskina’s lab had generally assumed that an AWH system in the field would absorb moisture during the night, and then use the heat from the sun during the day to naturally evaporate the water and condense it for collection. 

“Any material that’s very good at capturing water doesn’t want to part with that water,” Boriskina explains. “So you need to put a lot of energy and precious hours into pulling water out of the material.” 

She realized there could be a faster way to recover water after Ikra Shuvo joined her group. Shuvo had been working with ultrasound for wearable medical device applications. When he and Boriskina considered ideas for new projects, they realized that ultrasound could be a way to speed up the recovery step in atmospheric water harvesting.

“It clicked: We have this big problem we’re trying to solve, and now Ikra seemed to have a tool that can be used to solve this problem,” Boriskina recalls.

Water dance

Ultrasound, or ultrasonic waves, are acoustic pressure waves that travel at frequencies of over 20 kilohertz (20,000 cycles per second). Such high-frequency waves are not visible or audible to humans. And, as the team found, ultrasound vibrates at just the right frequency to shake water out of a material. 

“With ultrasound, we can precisely break the weak bonds between water molecules and the sites where they’re sitting,” Shuvo says. “It’s like the water is dancing with the waves, and this targeted disturbance creates momentum that releases the water molecules, and we can see them shake out in droplets.”

Shuvo and Boriskina designed a new ultrasonic actuator to recover water from an atmospheric water harvesting material. The heart of the device is a flat ceramic ring that vibrates when voltage is applied. This ring is surrounded by an outer ring that is studded with tiny nozzles. Water droplets that shake out of a material can drop through the nozzle and into collection vessels attached above and below the vibrating ring. 

They tested the device on a previously designed atmospheric water harvesting material. Using quarter-sized samples of the material, the team first placed each sample in a humidity chamber, set to various humidity levels. Over time, the samples absorbed moisture and became saturated. The researchers then placed each sample on the ultrasonic actuator and powered it on to vibrate at ultrasonic frequencies. In all cases, the device was able to shake out enough water to dry out each sample in just a few minutes. 

The researchers calculate that, compared to using heat from the sun, the ultrasonic design is 45 times more efficient at extracting water from the same material. 

“The beauty of this device is that it’s completely complementary and can be an add-on to almost any sorbent material,” says Boriskina, who envisions a practical, household system might consist of a fast-absorbing material and an ultrasonic actuator, each about the size of a window. Once the material is saturated, the actuator would briefly turn on, powered by a solar cell, to shake out the water. The material would then be ready to harvest more water, in multiple cycles throughout a single day.  

“It’s all about how much water you can extract per day,” she says. “With ultrasound, we can recover water quickly, and cycle again and again. That can add up to a lot per day.” 

This work was supported, in part, by the MIT Abdul Latif Jameel Water and Food Systems Lab and the MIT-Israel Zuckerman STEM Fund.

###

Written by Jennifer Chu, MIT News

 

ARC at Sheba Medical Center and Mount Sinai launch collaboration with NVIDIA to crack the hidden code of the human genome through AI



Three-year partnership aims to harness LLMs to decode the 98% of the genome that remains unexplored, paving the way for improved disease prevention and precision medicine




The Mount Sinai Hospital / Mount Sinai School of Medicine

 




RAMAT GAN, Israel and New York, NY — November 18, 2025 — ARC Innovation at Sheba Medical Center and Icahn School of Medicine at Mount Sinai (part of the Mount Sinai Health System in New York City) today announced a landmark three-year collaboration with NVIDIA to harness the power of artificial intelligence for genomic discovery through the application of large language model (LLM) technology.

The initiative aims to pioneer the decoding of the majority of the human genome that remains poorly understood in order to unlock new pathways for disease prevention, diagnosis, and treatment. Over the three-year period, the project will be supported by significant investment from the participating organizations, with the goal of accelerating research that can ultimately benefit patients worldwide.

The collaboration brings together three global leaders across health care, technology, and research: Sheba and Icahn School of Medicine will contribute extensive genomic datasets, AI research capabilities, and clinical insight, while NVIDIA will provide its advanced computational architecture and AI development platforms, software, and scientific expertise. Together, the institutions will create an AI-driven genomic research engine capable of identifying patterns and regulatory mechanisms that link genetic variation to disease risk and therapeutic response.

“While approximately two percent of the human genome has been thoroughly characterized, the remaining 98 percent, which was once labeled junk DNA, is increasingly recognized as containing critical regulatory and functional elements,” said Prof. Gidi Rechavi, MD, PhD, Israel Prize laureate, Head of the Sheba Cancer Research Center and the Wohl Institute of Translational Medicine, and initiator of the project. “Moreover, when individual genomes are sequenced, significant differences are observed. The genomic LLM approach at the heart of this pivotal collaboration aims to decipher the basic function of human genomic sequences and to enable the use of their variability as a key to diagnosis and future therapy.”

“This collaboration is an important step toward a future where every person can benefit from the power of whole genome sequencing,” said Alexander Charney, MD, PhD, Director of the Charles Bronfman Institute for Personalized Medicine, Vice Chair, Windreich Department of Artificial Intelligence and Human Health, and Associate Professor of Artificial Intelligence and Human Health, Psychiatry, Genetics and Genomic Sciences, and Neuroscience at the Icahn School of Medicine at Mount Sinai. “By bringing advanced AI into genomic research, we’re moving closer to making personalized, precision medicine a reality for all.”

“AI has the power to unlock the secrets of the human genome and transform health care for billions of people worldwide,” said Dr. Nati Daniel and Dr. Yoli Shavit, Applied AI Architecture at NVIDIA. “The development of a state-of-the-art Genomic Foundation Model (gFM), brings together clinicians, geneticists, bioinformaticians, and AI researchers to tackle one of science’s greatest challenges with NVIDIA’s full-stack AI platform.”

At Mount Sinai, the initiative will be anchored within the larger Mount Sinai Million Health Discoveries Program. The program, founded and led by Dr. Charney, is the flagship initiative of CBIPM, the Windreich Department of Artificial Intelligence and Human Health, and the Hasso Plattner Institute for Digital Health at Mount Sinai. It brings together genomics, AI, and clinical translation to advance precision medicine in the real world.

“This partnership exemplifies the power of global collaboration at the intersection of science, medicine, and technology,” said Eric J. Nestler, MD, PhD, the Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai. “By working with Sheba Medical Center and NVIDIA, we are unlocking new possibilities to decode the vast, uncharted regions of the human genome and advance discoveries that will benefit patients worldwide.”

“This collaboration unites three global powerhouses to push the boundaries of what’s possible in medicine,” said Prof. Eyal Zimlichman, Director of ARC and Chief Innovation, Transformation and AI Officer at Sheba Medical Center, and Avner Halperin, CEO of Sheba Impact at ARC. “Only by combining the unique strengths of the three partnering organizations can we solve one of the toughest challenges in healthcare that touches at the very core of how the human body works. This allows us to take AI to a place where it empowers a fundamental transformation in healthcare—accelerating scientific discovery, strengthening health systems, improving healthcare outcomes globally, and driving new economic value throughout the ecosystem.”

The initiative’s initial focus will be on areas of medicine where genetic complexity has long hindered scientific progress. The platform will analyze the interplay of thousands of genomic regions to help researchers identify underlying mechanisms that contribute to disease and to uncover potential therapeutic targets.

At Sheba, the project was made possible due to the work of Dr. Omri Nayshool and Dr. Tal Zinger from the Cancer Research Center, Dr. Dan Dominissini from the Laboratories Division, and Raizy Kellerman, Dan Ofer, and Guy Leib from ARC Innovation.

The collaboration will be co-led by ARC’s newly established AI Center at Sheba, which serves as a hub for global partnerships advancing the intersection of medicine and AI, together with Mount Sinai’s Charles Bronfman Institute for Personalized Medicine and Windreich Department of Artificial Intelligence and Human Health, serving as a unified engine for accelerating breakthroughs at the nexus of genomics, data science, and AI-driven clinical innovation.

Joint research teams from all three institutions have already begun laying the foundations for a shared platform that will support scientists and clinicians worldwide.

###

About Sheba Medical Center

The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation. Sheba’s City of Health unites specialty hospitals, research and simulation centers, a virtual hospital, and its innovation arm ARC (Accelerate, Redesign, Collaborate), which connects entrepreneurs and clinicians to advance the development and implementation of new AI and tech solutions in healthcare, and accelerates the adoption of innovation both within the hospital and with health systems worldwide. Sheba is one of the top-ten hospitals in the world, having been ranked a World’s Best Hospital by Newsweek for the last seven consecutive years (2019-2025). For more information, visit: https://sheba-global.com or https://arcinnovation.org/.

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population. The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows. Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai

 

GSK and Fleming Initiative scientists unite to target AMR with advanced AI





Dr Andrew Edwards, microbiologist at Imperial College London 

image: 

Dr Andrew Edwards, Associate Professor in Molecular Microbiology, Department of
Infectious Disease and Centre for Bacterial Resistance Biology at Imperial College London.
Dr Edwards is one of the researchers investigating Gram-negative bacteria. One of the new
research initiatives aims to find solutions to bacterial defences. Gram-negative bacteria have
a complex cell envelope defence system which prevents antibiotics from accumulating
inside the cell, and efflux pumps that can eject those that do.

view more 

Credit: Thomas Angus / Imperial College London




IMPERIAL COLLEGE LONDON PRESS RELEASE 

FOR IMMEDIATE RELEASE: Tuesday 18th November 2025


·       £45m GSK funding allocated to six new research programmes  combining expertise and using cutting edge AI technology to accelerate AMR research

·       Leading AMR experts from Imperial College London and GSK unite to target WHO priority pathogens: Gram-negative bacteria, Aspergillus, Staph aureus (including MRSA)

·       Initiative funds around 50 dedicated UK scientific and academic roles focused entirely on AMR research

·       These critical projects aim to enhance understanding and advance solutions to the urgent public health threat of AMR and drug-resistant infections

GSK and the Fleming Initiative today announced six major new research programmes, called ‘Grand Challenges’ which harness some of the best scientific expertise and the latest technologies, including advanced AI, to find new ways to slow the progress of antimicrobial resistance (AMR). 

According to the recent (October 2025) WHO GLASS Report highlighting a worsening global AMR situation, around one in six laboratory confirmed bacterial infections were caused by bacteria resistant to antibiotics. Annual deaths associated with AMR are predicted to rise by 74.5% from 4.71m in 2021 to 8.22 million in 2050.[1] 

All of the new programmes announced today will begin by early 2026, are fully funded for 3 years and will cover six key themes: 

·      Supercharging the discovery of new antibiotics for Gram-negative bacterial infections

·      Accelerating the discovery of new drugs to combat fungal infections 

Improving understanding of how our immune systems respond to drug-resistant bacteria, starting with Staphylococcus aureus, to stimulate vaccines research

·      Using disease surveillance and environmental data to create AI models that predict how drug-resistant pathogens emerge and spread 

·      Running an innovative clinical trial to improve how and when antibiotics are prescribed  

·      Using international research data and insights to inform policy and public engagement, embed preventative interventions, accelerate continued R&D, and amplify societal and government action to get ahead of AMR

The Fleming Initiative – a groundbreaking collaboration established by Imperial College London and Imperial College Healthcare NHS Trust - brings together research scientists, policymakers, clinicians, behavioural experts, public and commercial partners to provide the networks, expertise and skills to provide equitable solutions to AMR at a global scale. GSK became the first founding partner of the Initiative, pledging £45m in funding in 2024 and backing the Fleming’s mission to help tackle AMR around the world and setting out a series of Grand Challenges.

One of the new research initiatives aims to find solutions to one of the major scientific hurdles in AMR which has consistently challenged the experts – breaking through the defences of Gram-negative bacteria, one of the most concerning threats to human health. These bacteria (which include E. coli, Klebsiella pneumoniae) have a complex cell envelope defence system which prevents antibiotics from accumulating inside the cell, and efflux pumps that can eject those that do. Turning the power of supercomputers on the superbugs, chemists, microbiologists and AI experts at Imperial’s Drug Discovery Hub will partner with GSK’s scientists and Agilent Technologies to use advanced automation and generate novel data sets on diverse molecules to create an AI/ML model that will enhance our ability to design antibiotics for multi-drug-resistant Gram-negative infections. These data and AI models will be made available to scientists around the world in the hope of accelerating the development of a new generation of antimicrobial drugs.

In a second Challenge announced today, scientists will drive the discovery of new drugs to combat fungal infections, starting with Aspergillus. Around two million cases of Aspergillus infection occur annually, with mortality rates upwards of 46% (in higher risk ICU patients),[2] further confounded by the spread of antifungal resistance. Only four types of drugs currently exist, typically targeting the same sites within the fungal cells. This new programme will use AI to identify the unique vulnerabilities of fungi to support the development of new, targeted drugs.

A third new team of experts will begin modelling the human immune response to infection, starting with Staphylococcus aureus, one of the most dangerous drug-resistant pathogens worldwide, leading to more than one million deaths annually.[3] Vaccines against this pathogen have so far failed in clinical trials due to a lack of detailed, human-relevant data on bacterial behaviour and immune responses. The new team will replicate, under strictly controlled and safe conditions, surgical site infections to provide key data on infection progression and the human immune response to S. aureus to inform new vaccine development.

In total, around 50 dedicated, multi-disciplinary scientific, clinical and academic roles will be funded by the GSK/Fleming AMR partnership and will be largely based in Imperial College London facilities in the UK. Through this, the collaboration will bring impetus to a vital field of research which has seen a declining workforce, increasingly struggling to attract the necessary scientific expertise, as highlighted by the AMR Industry Alliance report, ‘Leaving the Lab’, in 2024.  All scientific research programmes are led by Imperial and GSK experts. 

Professor Lord Ara Darzi, Executive Chair of the Fleming Initiative, said: “In the 12 months since we announced our landmark partnership between GSK and the Fleming Initiative, a huge amount of progress has been made. Through our convening power, we have the world-leading expertise, facilities, capacity and vision in place to be able to launch these ambitious Grand Challenges.

“Today, in the shadow of 80 years since the Nobel prize for the discovery of penicillin, we’re delighted to see this research progress. We hope this research will be a beacon for the global scientific community and highlight the urgent need for collaborative efforts to tackle the rising global threat of antimicrobial resistance.”

 

Tony Wood, Chief Scientific Officer, GSK, said: “I’m delighted to combine GSKs leadership in antimicrobial science with world-leading research at Imperial College London. Together, with scaled datasets, emerging drug modalities and AI-driven models, we will open up new approaches for the discovery of novel antibiotics as well as anticipate and outpace the development of resistance to transform the treatment and prevention of serious infections. Currently, GSK has a promising portfolio of relevant assets in development, many targeting pathogens identified as priorities by WHO and US CDC. We will continue to be a leader in inspiring much more collective action, across industry, academia and policy and I believe our partnership with the Fleming Initiative is an important new step in that direction.”    

Professor Hugh Brady, President of Imperial College London, said: “Antimicrobial resistance is a global challenge that no single lab or institution can solve alone. Tackling the rise of drug-resistant infections can only be done by bringing together a wide range of expertise – from across science, industry and policy, alongside public engagement. This is convergence science in action and will ensure antimicrobials continue to work for future generations.”

Professor Tim Orchard, chief executive of Imperial College Healthcare NHS Trust said: “Antimicrobial resistance is one of the biggest challenges we face in the NHS and across the world. Drug-resistant infections are increasingly difficult to treat and pose a growing risk to patients. We urgently need new solutions and interventions for tackling drug-resistant infections, which will only be achieved if we pool our expertise. These ambitious research initiatives are a fantastic example of this type of collaboration and how the Fleming Initiative will benefit both local and global communities.”

Data and insights from these programmes will be disseminated broadly with the intent to inspire development of new, more effective medicines and vaccines globally.

The news of the launch of the six Grand Challenges coincides with two significant milestones – World AMR Awareness Week and the 80th anniversary of the Nobel Prize award for the development of penicillin, the first broad spectrum antibiotic.

Also closely following the WHO GLASS report on worsening AMR, this major step is a timely call to action to the global scientific community for the urgent collaborative work required to prevent a steep increase in AMR deaths over the next 25 years. 

-

NOTES TO EDITORS

[1] ‘Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis’. The Lancet, 2022. DOI: https://doi.org/10.1016/S0140-6736(21)02724-0  

[2] ‘Denning DW. Global incidence and mortality of severe fungal disease’. Lancet Infect Dis. 2024. DOI: https://doi.org/10.1016/S1473-3099(23)00692-8

[3] ‘Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019’. The Lancet, 2022. DOI: https://doi.org/10.1016/S0140-6736(22)02185-7

IMAGES
A selection of images from Imperial College London are available for use with the press release only. Please see 'Description and credits' for image details and credits.
https://imperialcollegelondon.box.com/s/wj46mcklm1f5gcwnzmq7gwpv7qauyq5z


About the Fleming Initiative
Jointly established by Imperial College London and Imperial College Healthcare NHS Trust in 2022, the Fleming Initiative brings together scientists, policymakers, clinicians, commercial partners and the public to provide equitable solutions to antimicrobial resistance at a global scale.

About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

About Imperial College London
We are Imperial – a world-leading university for science, technology, engineering, medicine and business (STEMB), where scientific imagination leads to world-changing impact

As a global top ten university in London, we use science to try to understand more of the universe and improve the lives of more people in it. Across our nine campuses and throughout our Imperial Global network, our 22,000 students, 8,000 staff, and partners work together on scientific discovery, innovation and entrepreneurship. Their work navigates some of the world’s toughest challenges in global health, climate change, AI, business leadership and more.  

Founded in 1907, Imperial’s future builds on a distinguished past, having pioneered penicillin, holography and fibre optics. Today, Imperial combines exceptional teaching, world-class facilities and a habit of interdisciplinary practice to unlock scientific imagination. https://www.imperial.ac.uk/

About Imperial College Healthcare NHS Trust
Imperial College Healthcare is one of the largest NHS Trusts in England, with over 15,000 staff providing acute and specialist healthcare to over one million people a year. The Trust runs five hospitals in central and west London - Charing Cross, Hammersmith, Queen Charlotte's and Chelsea, St Mary's and the Western Eye.  Find out more: www.imperial.nhs.uk

The human costs of climate overshoot





PNAS Nexus

overshoot 

image: 

Climate risk is higher in pathways reaching a temperature level by the end of the century with climate overshoot, i.e., temporarily exceeding a temperature level and then returning to that lower temperature, as compared to pathways reaching the same temperature level without overshoot. The higher and the longer the overshoot is, the greater climate impacts are expected within social and humanitarian systems.

view more 

Credit: Kruczkiewicz et al.





In a Perspective, the authors suggest that the social and humanitarian impacts of overshooting the Paris Agreement’s aspirational goal of a 1.5 degrees Celsius rise in global mean temperature remain largely unknown, despite robust knowledge of physical climate impacts. Andrew Kruczkiewicz and colleagues outline five factors that policymakers and planners should take into account when considering the human impacts of climate overshoot: peak warming and duration of overshoot, localized amplification of effects, timing of arrival, adaptation limits, and dynamics of overshoot reversal. The authors note that emissions levels agreed-upon in theory through international negotiations put the world on track to significantly exceed 1.5 degrees Celsius global mean temperature before the 2050s, likely resulting in decades of climate overshoot. The authors argue that both the magnitude and duration of overshoot must be limited as much as possible and the 1.5 degree warming threshold should remain the target to secure a liveable future. But bringing the temperature back down post-peak could be a bumpy road, with periods of increase, decrease, and stability in global mean temperature, rather than a smooth decline. The authors call for further investigation into the potential impacts post-peak, including assessment and communication of uncertainty related to various scenarios. Different recovery trajectories would have distinct implications for humanitarian needs, disaster risk management including early warning systems, climate finance priorities, and infrastructure development. The authors call for enhanced research on potential human and social impacts of overshoot, improved planning by humanitarian organizations for irreversible changes, and strengthened national climate commitments. According to the authors, understanding how social and economic systems will be impacted during climate overshoot is necessary to identify, tailor, and implement appropriate adaptation and risk reduction strategies in the years and decades ahead. Further, the authors note this work is of increased importance as it coincides with the run-up to COP30 in Brazil, where overshoot and how to address the related risks are of increasing concern.

NOTE: An earlier version of the author’s final manuscript, as accepted for publication by the journal, but prior to copyediting or typesetting, was published on October 18, 2025.